Evaluation of sialidase NEU3 effect on cell viability with or without gefitinib.
Matilde Forcella
Monica Oldani
Samantha Epistolio
Stefania Freguia
Eugenio Monti
Paola Fusi
Milo Frattini
10.1371/journal.pone.0187289.g004
https://plos.figshare.com/articles/figure/Evaluation_of_sialidase_NEU3_effect_on_cell_viability_with_or_without_gefitinib_/5557231
<p>MTT test was performed on HSAEC1, HCC4006 and H1734 cell lines transfected with either the empty vector (mock) or pcDNA3.1-HsNEU3 and then treated or not with 27 nM or 1 μM gefitinib for 36 h <i>post</i>-transfection. Data were normalized on control cells transfected with the empty vector (A). Cell viabilities of mock and NEU3 transfected cells are reported after treatment with either 27 nM (B) or 1 μM gefitinib (C). Data were normalized on control cells without drug. Values are presented as means ± standard error (SE).</p>
2017-10-31 17:47:15
therapies sensitivity
NSCLC cell viability
NEU 3
EGFR point mutations
TKI
Non-Small Cell Lung Cancer
Akt pathway
NEU 3 overexpressing patients
ERK pathway
lung cancer cell lines
plasma membrane-associated NEU 3 Adenocarcinoma
sialidase NEU 3
EGFR pathways activation
NEU 3 overexpression
mucosa cell line
Non-small cell lung cancer
sialidase NEU 3 overexpression
EGFR wild-type gene sequence